Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

  • End date
    Dec 9, 2024
  • participants needed
  • sponsor
    Ludwig-Maximilians - University of Munich
Updated on 9 December 2021
serum bilirubin level
kidney function tests
neutrophil count
liver metastasis
folfox regimen
adjuvant chemotherapy
folfiri regimen
adenocarcinoma of colon


The FIRE-4 study aims to define a treatment concept for patients with RAS wild-type tumours, optimised with regard to overall survival. The first-line treatment will be conducted with FOLFIRI plus cetuximab, which resulted in a significantly prolonged overall survival versus bevacizumab in the FIRE-3 study. Following initial progression (PD1) it is recommended that the treatment be continued with FOLFOX plus bevacizumab, as this concept led to significantly prolonged survival in the E3200 study. Owing to the encouraging results of the Santini study , a cetuximab rechallenge in combination with irinotecan-based chemotherapy is to be performed as part of the third-line treatment in patients who showed a response defined according to RECIST 1.1 during the first-line treatment (tumour diameter < -30%) or presented with stable tumour disease for at least 6 months (tumour diameter +20 to -30%). The concept of the ideal sequence has not yet been studied to date in a clinical trial.


The study will begin with FPFV: (first study visit of the first patient, signing the declaration of consent to participate in the study): scheduled for the 4th quarter of 2014

Patient recruitment: 36 months

Treatment duration per patient: Until the time of progression under the third-line treatment at the latest. Anticipated individual duration of treatment: 24 months (for patients who undergo all three treatment lines -included in part 1), or 6 months in patients who only receive third line treatment (included directly in part 2)

Duration of follow-up after the end of treatment: For all patients, until death or for at least 1 year following final termination of any study treatment regardless of the treatment line. In so doing, the follow-up period for patients included in part 1 of the study will be conducted for a maximum of 5 years from the time of randomisation 1; and for patients included in only part 2 of the study (third-line treatment), for a maximum of 3 years from the date of randomisation 2.

End of the study: last follow-up visit of the last study patient scheduled for the 4th quarter of 2020

Condition Metastatic Colorectal Cancer
Treatment Capecitabine, Cetuximab, Regorafenib, bevacizumab, Irinotecan, 5-FU, Folinic Acid, Irinotecan 125mg, Cetuximab wkly
Clinical Study IdentifierNCT02934529
SponsorLudwig-Maximilians - University of Munich
Last Modified on9 December 2021


Yes No Not Sure

Inclusion Criteria

Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum (metastatic colorectal cancer), primarily nonresectable or with surgery refused by the patient
RAS wild-type tumour status (KRAS and NRAS exon 2-4) (proven in the primary tumour or metastasis) at any timepoint of randomisation
Age 18
ECOG performance status 0-1
Patients suitable for chemotherapy administration
Patient's written declaration of consent obtained
Estimated life expectancy > 3 months
Presence of at least one measurable reference lesion according to the RECIST 1.1 criteria (chest and abdominal CT 4 weeks or less before randomisation)
Primary tumour tissue available and patient consents to storage and molecular and genetic profiling of blood, plasma and tumour material (patients included directly at Part 2 of the study in whom primary tumour material is no longer available may be included in the study, provided that tumour material from the compulsory biopsy on progression following second-line treatment is available)
Effective contraceptive measures in men and in women of childbearing age (Pearl index <1)
Adequate haematopoietic function
Leukocytes 3.0 x 109/L with neutrophils 1.5 x 109/L
Thrombocytes 100 x 109/L
Haemoglobin 5.6 mmol/L (equivalent to 9 g/dL)
Adequate hepatic function
Serum bilirubin 1.5 x upper normal limit
ALAT and ASAT 2.5 x upper normal limit (in the presence of hepatic metastases, ALAT and ASAT 5 x upper normal limit)
INR < 1.5 and aPTT < 1.5 x upper normal limit (patients without anticoagulation). Therapeutic anticoagulation is allowed if INR and aPTT have remained stable within the therapeutic range for at least 2 weeks
Adequate renal function
Serum creatinine 1.5 x upper normal limit or creatinine clearance (calculated according to Cockcroft and Gault) 50ml/min
adequate cardiac function: ECG and echocardiogram with a LVEF of 55%
Any significant toxicities of previous treatments must have resolved or stabilised
Last administration of an anti-EGFR substance 4 months before randomisation 2
Inclusion criterion solely for Part 1
No previous chemotherapy for metastatic disease
Time since last administration of a previous adjuvant chemotherapy >6 months
Additional inclusion criteria solely for Part 2
Former first-line treatment of the metastatic colorectal cancer with FOLFIRI and cetuximab; data available for the duration of treatment and the response within the context of first-line treatment
Former second-line treatment of the colorectal cancer without FOLFIRI, irinotecan or an anti-EGFR substance with data available for the substances administered, duration of treatment and response within the context of the second-line treatment
Proof of a RAS wild-type tumour (KRAS and NRAS exons 2-4) in a tumour biopsy (metastasis) within 4 weeks before randomisation
CT examinations with evidence of a partial response (PR) or complete response (CR) or stable disease (SD) 6 months according to RECIST Version 1.1 criteria as best response within the context of the first-line treatment with FOLFIRI and cetuximab

Exclusion Criteria

Proof of a RAS mutation (KRAS or NRAS, exons 2-4 in the tumour (proven in the primary tumour or metastasis) or absence of testing for RAS mutation
Primarily resectable metastases and the patient wishes for resection
Grade III or IV heart failure (NYHA classification)
Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or without stenting within the past 12 months before inclusion in the study
Pregnancy (exclusion to be ascertained by a beta hCG test) or breast feeding
Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study
Additional cancer treatment (chemotherapy, radiation, immune therapy or hormone treatment) during the study treatment in first-line and third-line treatment (treatments that are conducted as part of an anthroposophic or homeopathic treatment approach, e.g. mistletoe therapy do not represent an exclusion criterion)
Previous chemotherapy for the colorectal cancer with the exception of adjuvant treatment, completed at least 6 months before entering the study (exclusion criterion solely for part 1)
Participation in a clinical study or experimental drug treatment within 30 days prior to inclusion or during participation in the study
Known hypersensitivity or allergic reaction to any of the following substances: 5-fluorouracil, cetuximab, oxaliplatin, irinotecan, bevacizumab and chemically related substances
Known or clinically suspected brain metastases
History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhoea
Symptomatic peritoneal carcinosis
Severe, non-healing wounds, ulcers or bone fractures
Uncontrolled hypertension
Marked proteinuria (nephrotic syndrome)
Arterial thromboemboli or severe haemorrhage within 6 months prior to inclusion in the study (with the exception of tumour bleeding before tumour resection surgery)
Haemorrhagic diathesis or tendency towards thrombosis
Known DPD deficiency (specific screening not required)
Known glucuronidation deficiency (Gilbert's syndrome) (specific screening not required)
History of a second malignancy during the past 5 years before inclusion in the study or during participation in the study, with the exception of a dermal basal cell or squamous cell carcinoma or cervical carcinoma in situ, if these were treated curatively
Known history of alcohol or drug abuse
A significant concomitant disease which, in the investigating physician's opinion, rules out the patient's participation in the study
Absent or restricted legal capacity
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note